Article Versions Notes

Guinn B-a, Schuler PJ, Schrezenmeier H, Hofmann S, Weiss J, Bulach C, Götz M, Greiner J. A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells. International Journal of Molecular Sciences. 2023; 24(11):9285. https://doi.org/10.3390/ijms24119285

Guinn, Barbara-ann, Patrick J. Schuler, Hubert Schrezenmeier, Susanne Hofmann, Johanna Weiss, Christiane Bulach, Marlies Götz, and Jochen Greiner. 2023. "A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells" International Journal of Molecular Sciences 24, no. 11: 9285. https://doi.org/10.3390/ijms24119285

Guinn, B. -a., Schuler, P. J., Schrezenmeier, H., Hofmann, S., Weiss, J., Bulach, C., Götz, M., & Greiner, J. (2023). A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells. International Journal of Molecular Sciences, 24(11), 9285. https://doi.org/10.3390/ijms24119285